Fig. 3From: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trialSubgroup analysis of total pathological complete response (tpCR) per independent central review. Differences between pyrotinib and placebo groups in each subgroup were shown, with the 95% CI being calculated using the Wald method. ER estrogen receptor, PR progesterone receptorBack to article page